Meiragtx Holdings Plc (MGTX)
NASDAQ:MGTX
Top Page
Meiragtx Holdings
(NASDAQ:MGTX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$9.00
▼(-20.00% Downside)
Action:ReiteratedDate:04/01/26
The score is held back primarily by weak financial fundamentals—large ongoing losses, continued cash burn, and a deteriorated capital structure with negative equity—despite strong recent revenue/gross margin improvement. Technicals are constructive with the stock in an uptrend, and corporate events add support via regulatory and partnership/financing developments, but valuation remains challenging given negative earnings.
Positive Factors
Revenue and gross margin recovery
A large 2025 revenue rebound and a material gross margin improvement indicate stronger product-market fit and improved unit economics. Sustained high gross margins can enable operating leverage as sales scale, reducing future funding needs and improving the path to durable profitability.
Negative Factors
Persistent deep unprofitability
Despite top-line growth, the company remains deeply unprofitable with very large negative margins. Ongoing structural operating losses mean earnings improvements require sustained revenue growth plus continued cost control; otherwise the company will need external capital repeatedly.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and gross margin recovery
A large 2025 revenue rebound and a material gross margin improvement indicate stronger product-market fit and improved unit economics. Sustained high gross margins can enable operating leverage as sales scale, reducing future funding needs and improving the path to durable profitability.
Read all positive factors
Meiragtx Holdings (MGTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$916.27M
Dividend YieldN/A
Average Volume (3M)341.94K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue Growth96.83%
EPS Growth-61.92%
CountryUS
Employees375
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.19
Shares Outstanding81,446,130
10 Day Avg. Volume395,771
30 Day Avg. Volume341,939
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue11.54
Enterprise Value/Gross Profit12.27
Enterprise Value/Ebitda-11.18
Forecast
1Y Price Target
$19.00Price Target Upside68.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.13
Revenue Forecast (FY)$124.69M
Meiragtx Holdings Business Overview & Revenue Model
Company Description
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia fo...
Meiragtx Holdings Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
22
Negative
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 81.39M | 33.28M | 14.02M | 15.92M | 37.70M |
| Gross Profit | 76.55M | 9.49M | 14.02M | 15.92M | 37.70M |
| EBITDA | -105.97M | -121.69M | -57.05M | -116.07M | -71.40M |
| Net Income | -114.20M | -147.79M | -84.03M | -129.62M | -79.56M |
Balance Sheet | |||||
| Total Assets | 244.43M | 269.75M | 326.74M | 318.24M | 320.16M |
| Cash, Cash Equivalents and Short-Term Investments | 65.93M | 103.66M | 129.57M | 115.52M | 137.70M |
| Total Debt | 88.69M | 84.80M | 89.26M | 92.25M | 23.73M |
| Total Liabilities | 250.22M | 201.92M | 188.57M | 200.50M | 134.76M |
| Stockholders Equity | -5.79M | 67.83M | 138.18M | 117.74M | 185.40M |
Cash Flow | |||||
| Free Cash Flow | -50.19M | -109.45M | -125.54M | -118.06M | -65.75M |
| Operating Cash Flow | -46.36M | -104.50M | -105.36M | -73.10M | -10.53M |
| Investing Cash Flow | -4.11M | 23.48M | 34.03M | -44.96M | -61.72M |
| Financing Cash Flow | 12.27M | 54.53M | 84.02M | 95.20M | 1.71M |
Meiragtx Holdings Technical Analysis
Positive
11.25
Price Trends
7.93
Positive
7.93
Positive
8.00
Positive
Market Momentum
0.66
Negative
79.67
Negative
80.70
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGTX, the sentiment is Positive. The current price of 11.25 is above the 20-day moving average (MA) of 8.51, above the 50-day MA of 7.93, and above the 200-day MA of 8.00, indicating a bullish trend. The MACD of 0.66 indicates Negative momentum. The RSI at 79.67 is Negative, neither overbought nor oversold. The STOCH value of 80.70 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGTX.
Meiragtx Holdings Risk Analysis
Meiragtx Holdings disclosed 79 risk factors in its most recent earnings report. Meiragtx Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Meiragtx Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $6.08B | -39.12 | -20.02% | ― | ― | 12.45% | |
57 Neutral | $5.66B | -8.47 | -32.00% | ― | ― | 45.66% | |
56 Neutral | $1.27B | ― | -56.64% | ― | -36.36% | -945.72% | |
54 Neutral | $916.27M | -5.60 | -1065.47% | ― | 96.83% | -61.92% | |
52 Neutral | $498.77M | -3.10 | -47.27% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
MGTX
Meiragtx Holdings
11.25
5.93
111.47%
TSHA
Taysha Gene Therapies
6.00
4.82
408.47%
FDMT
4D Molecular Therapeutics
9.77
6.86
235.74%
TERN
Terns Pharmaceuticals
52.71
50.47
2253.12%
ERAS
Erasca
18.20
17.03
1455.56%
Meiragtx Holdings Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
MeiraGTx Highlights Breakthrough Gene Therapy and Strategic Alliances
Positive
Mar 26, 2026
On March 25, 2026, MeiraGTx amended its notes purchase and warrant agreements with Perceptive Credit Holdings, extending note maturity to May 2, 2027, committing to redeem $25 million of principal by June 30, 2026, and cutting the warrant exercise...
Business Operations and StrategyStock Buyback
MeiraGTx Announces Share Repurchase and Investor Lock-Up
Positive
Jan 2, 2026
On December 31, 2025, MeiraGTx Holdings plc agreed to repurchase 2.3 million of its ordinary shares from Perceptive Life Sciences Master Fund, an affiliate of Perceptive Advisors, at $7.91 per share, matching the Nasdaq volume-weighted average pri...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.